Scholarlink

Background <p>Accurately predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) early during treatment could enable therapy adaptation. Total choline (tCho) measured by Proton MR spectroscopy (<sup>1</sup>H-MRS) reflects tumor metabolism and may serve as an early biomarker, but its predictive performance requires further validation.</p> Objectives <p>To investigate the performance of tCho in singlevoxel <sup>1</sup>H-MRS to early predict pCR to NAC in breast cancer patients.</p> Materials &amp; methods <p>Patients with primary invasive breast cancer scheduled for NAC were prospectively enrolled from August 2021 to October 2023. The concentration of tCho was measured with <sup>1</sup>H-MRS at four time points: T0 (pretreatment), T1, T2, and T3 (after 2, 4, and 6 NAC cycles respectively). The tCho were compared among the four time points and between pCR and non-pCR groups. The diagnostic performance was evaluated using the area under the receiver operating characteristic curves (AUC).</p> Results <p>191 patients were enrolled, including 136 patients with non-pCR and 55 patients with pCR. The dynamic changes of tCho showed a downward trend during NAC in the pCR group, non-pCR group, and all molecular subtypes. Among the total patients, tCho at four time points were higher in the non-pCR group than those in the pCR group (all <i>P</i> &lt; 0.05), and with an AUC of 0.72 at T0. In the Luminal B, HER2-enriched and triple-negative subgroups, tCho at T0 were higher in the non-pCR group than that in the pCR group (all <i>P</i> &lt; 0.05). In all patients, tCho combined with the PR and HER2 at T0 showed good predicting performance, with an AUC of 0.85.</p> Conclusions <p>tCho could be used as an early predictor of pCR during NAC in breast cancer patients. This may assist in guiding the clinical selection of individualized and effective treatment programs.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early prediction of pathologic complete response to neoadjuvant chemotherapy based on longitudinal total choline of MR spectroscopy in patients with breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月16日

查看全文
  • Shuling Liu,
  • Xiaoxia Wang,
  • Fujie Jiang,
  • Sun Tang,
  • Ying Cao,
  • Lu Wang,
  • Huifang Chen,
  • Xiangfei Zeng,
  • Yao Huang,
  • Lan Li,
  • Renzhi Zhang,
  • Jiuquan Zhang

摘要

Background

Accurately predicting pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) early during treatment could enable therapy adaptation. Total choline (tCho) measured by Proton MR spectroscopy (1H-MRS) reflects tumor metabolism and may serve as an early biomarker, but its predictive performance requires further validation.

Objectives

To investigate the performance of tCho in singlevoxel 1H-MRS to early predict pCR to NAC in breast cancer patients.

Materials & methods

Patients with primary invasive breast cancer scheduled for NAC were prospectively enrolled from August 2021 to October 2023. The concentration of tCho was measured with 1H-MRS at four time points: T0 (pretreatment), T1, T2, and T3 (after 2, 4, and 6 NAC cycles respectively). The tCho were compared among the four time points and between pCR and non-pCR groups. The diagnostic performance was evaluated using the area under the receiver operating characteristic curves (AUC).

Results

191 patients were enrolled, including 136 patients with non-pCR and 55 patients with pCR. The dynamic changes of tCho showed a downward trend during NAC in the pCR group, non-pCR group, and all molecular subtypes. Among the total patients, tCho at four time points were higher in the non-pCR group than those in the pCR group (all P < 0.05), and with an AUC of 0.72 at T0. In the Luminal B, HER2-enriched and triple-negative subgroups, tCho at T0 were higher in the non-pCR group than that in the pCR group (all P < 0.05). In all patients, tCho combined with the PR and HER2 at T0 showed good predicting performance, with an AUC of 0.85.

Conclusions

tCho could be used as an early predictor of pCR during NAC in breast cancer patients. This may assist in guiding the clinical selection of individualized and effective treatment programs.